Molecular Tumor Boards in Clinical Practice

Claudio Luchini; Rita T Lawlor; Michele Milella; Aldo Scarpa

doi:10.1016/j.trecan.2020.05.008

Molecular Tumor Boards in Clinical Practice

Trends Cancer. 2020 Sep;6(9):738-744. doi: 10.1016/j.trecan.2020.05.008. Epub 2020 Jun 6.

Authors

Claudio Luchini¹, Rita T Lawlor², Michele Milella³, Aldo Scarpa⁴

Affiliations

¹ Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy. Electronic address: claudio.luchini@univr.it.
² ARC-Net Research Center, University and Hospital Trust of Verona, Verona, Italy.
³ Section of Oncology, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy. Electronic address: michele.milella@univr.it.
⁴ Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy; ARC-Net Research Center, University and Hospital Trust of Verona, Verona, Italy.

PMID: 32517959
DOI: 10.1016/j.trecan.2020.05.008

Abstract

Next-generation sequencing (NGS) application in clinical practice requires the implementation of molecular tumor boards (MTBs). Starting from a systematic review of literature, we discuss the MTB-related key points: MTB aims and composition, types of tumors to discuss, types of molecular analyses, methods for classifying actionability, appropriate turnaround time, and cost management.

Keywords: MTB; molecular tumor board; personalized medicine; precision oncology; target therapy.

Publication types

Research Support, Non-U.S. Gov't
Systematic Review

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / antagonists & inhibitors
Biomarkers, Tumor / genetics*
Clinical Decision-Making
Consensus
DNA Mutational Analysis / standards
Drug Resistance, Neoplasm / genetics
Genetic Testing / methods
Genetic Testing / standards
Genetic Testing / trends
Group Processes
High-Throughput Nucleotide Sequencing / standards
Humans
Medical Oncology / methods*
Medical Oncology / organization & administration
Medical Oncology / trends
Molecular Targeted Therapy
Mutation
Neoplasms / diagnosis
Neoplasms / drug therapy*
Neoplasms / genetics
Patient Care Team / organization & administration*
Precision Medicine / methods*
Precision Medicine / trends

Substances

Antineoplastic Agents
Biomarkers, Tumor